The nation of Zimbabwe has turned down a significant American healthcare agreement valued at $367m (£272m) spanning five years over Washington's insistence on sensitive biological samples.
This move was revealed after a internal memorandum dated December was disclosed, revealing that President Emmerson Mnangagwa deemed the arrangement was "skewed".
An official representative later explained that the US was requesting biological samples for research and profit but was not willing to guarantee the benefits from any future vaccines.
"We are forced to start the difficult and regrettable task of winding down our health assistance in Zimbabwe," remarked American envoy to Zimbabwe Pamela Tremont in a statement.
Her embassy indicated the US had furnished more than $1.9bn as health assistance to Zimbabwe during the past twenty years.
A doctors' association in Zimbabwe has urged further talks to find a deal suitable to all parties so the country's critical HIV programme can continue.
Wider Background
This development comes after a comparable case in Kenya, where a court suspended a similar health funding agreement after concerns were raised about the safety of Kenyans' health data.
Since resuming office last year, US President Donald Trump has reduced foreign aid and shut down the US Agency for International Development (USAID).
USAID had administered assistance for the American government, but Trump stated its spending was "wasteful" and his government was pursuing government-to-government deals to boost transparency and responsibility.
Based on statements, 16 nations in Africa have to date signed similar agreements, constituting more than $18.3bn in new funding.
Specifics of the Rejected Deal
This assistance for Zimbabwe would have supported "combating HIV/Aids, tuberculosis, malaria, healthcare for mothers and children, and preparing for epidemics".
"It is our view this collaboration might have yielded immense benefits for the people of Zimbabwe, particularly the 1.2 million currently receiving HIV treatment through American-funded programmes," Tremont commented.
However, government spokesperson Nick Mangwana maintained the proposed deal was "asymmetrical".
"Zimbabwe was being asked to surrender its genetic material and health information for a long time, with no equivalent assurance of access to any medical innovations – such as new medicines or tests – that could be developed from that shared data," he stated.
"In essence, our nation would provide the raw materials for medical research with no assurance that the end products would be accessible to our population if a future pandemic emerge."
National Interest and Global Health
Mangwana further said that the American exit from the global health body and its pursuit of bilateral health agreements were undermining frameworks already established through the global organization.
The spokesperson gave as an example its Pathogen Access and Benefit Sharing scheme created to manage potential global health emergencies.
"This system is intended to ensure that when a nation provides its information, the resulting advantages – including vaccines and treatments – are distributed fairly, not monopolised exclusively by those with the resources to develop them."
Zimbabwe's reservations over the US deal "should not be misconstrued as hostility towards the US," Mangwana stressed.
"We encourage continued dialogue with our American counterparts on how future co-operation might be designed in a way that honours the sovereignty and interests of both nations."
Medical Community Response
A leading public health body stated it understood the government's concerns, but urged that negotiations need to persist given that much of the nation's Aids initiatives depended on international support.
"In cases where specific concerns arise, including those relating to data governance or agreement terms, these can often be addressed via detailed discussion and negotiated safeguards," the group commented.
The halted deal emphasises the ongoing debate between receiving crucial foreign assistance and safeguarding national sovereignty in an ever more interconnected world.